Dr. Butt obtained his Ph.D. degree in Molecular Biology from The University of Glasgow, Scotland, He was a Staff Fellow at the National Institutes of Health, Bethesda, MD, before joining SmithKline Beckman (now GSK) Pharmaceuticals. He was Assistant Director in Research and Development at Smith Kline. He also served as Adjunct Professor Biochemistry and Biophysics, University of Pennsylvania Medical School, Philadelphia (1989-2000). He has published over 100 papers in life sciences research. Dr. Butt serves as an Adjunct Professor in Biomedical Engineering at Drexel University, Philadelphia. At Progenra he is spearheading the effort to target ubiquitin pathway enzyme for immune oncology. Progenra’s USP7 small molecules inhibitors have demonstrated dual anti-tumor activities. USP7 inhibitors directly block tumor cell growth as well as suppress Tregs thereby unleashing anti-tumor Teffector responses. Data shows that USP7 inhibitors have potent anti-tumor activity as a small molecule, single agent that is superior to Yervoy, Keytruda, Opdivo.